Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Andreozzi GM, Bignamini AA, Davì G, Palareti G, Matuška J, Holý M, Pawlaczyk-Gabriel K, Džupina A, Sokurenko GY, Didenko YP, Andrei LD, Lessiani G, Visonà A; SURVET Study Investigators. Andreozzi GM, et al. Among authors: matuska j. Circulation. 2015 Nov 17;132(20):1891-7. doi: 10.1161/CIRCULATIONAHA.115.016930. Epub 2015 Sep 25. Circulation. 2015. PMID: 26408273 Free PMC article. Clinical Trial.
Anticoagulation Duration After First Venous Thromboembolism: Real-Life Data From the International, Observational WHITE Study.
Palareti G, Bignamini AA, Cini M, Li YJ, Urbanek T, Madaric J, Bouslama K, Sokurenko GY, Andreozzi GM, Matuška J, Mansilha A, Barinov V. Palareti G, et al. Among authors: matuska j. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211049402. doi: 10.1177/10760296211049402. Clin Appl Thromb Hemost. 2021. PMID: 34841907 Free PMC article.
Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries-the prospective, international, observational WHITE study.
Palareti G, Bignamini A, Cini M, Li YJ, Urbanek T, Madaric J, Bouslama K, Sokurenko GY, Andreozzi GM, Matuška J, Mansilha A, Barinov V; WHITE study group. Palareti G, et al. Among authors: matuska j. Intern Emerg Med. 2022 Jan;17(1):71-82. doi: 10.1007/s11739-021-02765-1. Epub 2021 Jul 27. Intern Emerg Med. 2022. PMID: 34313959 Free PMC article.
Influence of clinical presentation, site, and extent of venous thrombosis on decision about duration of anticoagulation: Data from the international, prospective, observational WHITE study.
Palareti G, Bignamini AA, Urbanek T, Cini M, Li YJ, Madaric J, Bouslama K, Sokurenko GY, Andreozzi GM, Matuška J, Mansilha A, Barinov V; WHITE study group. Palareti G, et al. Among authors: matuska j. Thromb Res. 2022 Mar;211:140-146. doi: 10.1016/j.thromres.2022.01.025. Epub 2022 Feb 4. Thromb Res. 2022. PMID: 35151009 Free article.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine.
Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy I, Falanga A, Fareed J, Papageorgiou C, Arellano RS, Agathagelou P, Antic D, Auad L, Banfic L, Bartolomew JR, Benczur B, Bernardo MB, Boccardo F, Cifkova R, Cosmi B, De Marchi S, Dimakakos E, Dimopoulos MA, Dimitrov G, Durand-Zaleski I, Edmonds M, El Nazar EA, Erer D, Esponda OL, Gresele P, Gschwandtner M, Gu Y, Heinzmann M, Hamburg NM, Hamadé A, Jatoi NA, Karahan O, Karetova D, Karplus T, Klein-Weigel P, Kolossvary E, Kozak M, Lefkou E, Lessiani G, Liew A, Marcoccia A, Marshang P, Marakomichelakis G, Matuska J, Moraglia L, Pillon S, Poredos P, Prior M, Salvador DRK, Schlager O, Schernthaner G, Sieron A, Spaak J, Spyropoulos A, Sprynger M, Suput D, Stanek A, Stvrtinova V, Szuba A, Tafur A, Vandreden P, Vardas PE, Vasic D, Vikkula M, Wennberg P, Zhai Z; Scientific Reviewer Committee. Gerotziafas GT, et al. Among authors: matuska j. Thromb Haemost. 2020 Dec;120(12):1597-1628. doi: 10.1055/s-0040-1715798. Epub 2020 Sep 13. Thromb Haemost. 2020. PMID: 32920811 Free PMC article. Review.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
41 results